The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study-Reference-Cited by-同舟云学术

The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study

Published:2017-05-23 Issue:32 Volume:8 Page:52072-52077
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Roccatello Dario¹²,Sciascia Savino¹²,Rossi Daniela¹,Alpa Mirella¹,Naretto Carla¹,Radin Massimo¹,Fenoglio Roberta¹,Baldovino Simone¹²,Menegatti Elisa¹

Affiliation:

1. Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

2. Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review;Biology;2022-12-06

2. Pathogenesis-based new perspectives of management of ANCA-associated vasculitis;Autoimmunity Reviews;2022-03

3. How the Availability of Anti-C5a Agents Could Change the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis;Kidney and Blood Pressure Research;2022

4. Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference;Nephrology (Saint-Petersburg);2021-01-21

5. Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies;Rheumatology;2021-01-20